2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.
Jan 16, 2026DOI: 10.1093/cid/ciaf355Journal ArticleCID
Written by: Nandita NadigAdarsh BhimrajKelly CawcuttKathleen ChiotosAmy L DzierbaArthur Y KimGreg S MartinJeffrey C PearsonAmy Hirsch ShumakerLindsey R BadenRoger BedimoVincent Chi-Chung ChengKara W ChewEric S DaarDavid V GliddenErica J HardySteven JohnsonJonathan Z LiChristine MacBrayneMari M NakamuraLaura RileyRobert W ShaferShmuel ShohamPablo TebasPhyllis C TienJennifer LovelessYngve Falck-YtterRebecca L MorganRajesh T Gandhi
Find these authors on Roon
AK
Dr. Arthur Kim
HIV/AIDS Medicine · MGH
SS
Dr. Shmuel Shoham
Transplant/Immunocompromised States · Johns Hopkins
Summary
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
AK
Dr. Arthur Kim
Infectious Disease · HIV & AIDS MedicineMassachusetts General Hospitalarthurkim